1283 related articles for article (PubMed ID: 14656927)
21. Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes.
Fiedler B; Wollert KC
Cardiovasc Res; 2004 Aug; 63(3):450-7. PubMed ID: 15276470
[TBL] [Abstract][Full Text] [Related]
22. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
[TBL] [Abstract][Full Text] [Related]
23. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
[TBL] [Abstract][Full Text] [Related]
24. Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.
Parsons SA; Millay DP; Wilkins BJ; Bueno OF; Tsika GL; Neilson JR; Liberatore CM; Yutzey KE; Crabtree GR; Tsika RW; Molkentin JD
J Biol Chem; 2004 Jun; 279(25):26192-200. PubMed ID: 15082723
[TBL] [Abstract][Full Text] [Related]
25. Regulation of calcineurin through transcriptional induction of the calcineurin A beta promoter in vitro and in vivo.
Oka T; Dai YS; Molkentin JD
Mol Cell Biol; 2005 Aug; 25(15):6649-59. PubMed ID: 16024800
[TBL] [Abstract][Full Text] [Related]
26. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
Liu Q; Chen Y; Auger-Messier M; Molkentin JD
Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
[TBL] [Abstract][Full Text] [Related]
27. Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.
Diedrichs H; Mei C; Frank KF; Boelck B; Schwinger RH
J Mol Med (Berl); 2004 Oct; 82(10):688-95. PubMed ID: 15322704
[TBL] [Abstract][Full Text] [Related]
28. A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis.
Chang CP; Neilson JR; Bayle JH; Gestwicki JE; Kuo A; Stankunas K; Graef IA; Crabtree GR
Cell; 2004 Sep; 118(5):649-63. PubMed ID: 15339668
[TBL] [Abstract][Full Text] [Related]
29. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro.
Pu WT; Ma Q; Izumo S
Circ Res; 2003 Apr; 92(7):725-31. PubMed ID: 12663489
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes.
Lunde IG; Kvaløy H; Austbø B; Christensen G; Carlson CR
J Appl Physiol (1985); 2011 Nov; 111(5):1278-89. PubMed ID: 21474694
[TBL] [Abstract][Full Text] [Related]
31. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling.
Kuwahara K; Wang Y; McAnally J; Richardson JA; Bassel-Duby R; Hill JA; Olson EN
J Clin Invest; 2006 Dec; 116(12):3114-26. PubMed ID: 17099778
[TBL] [Abstract][Full Text] [Related]
32. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
33. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.
Antos CL; McKinsey TA; Frey N; Kutschke W; McAnally J; Shelton JM; Richardson JA; Hill JA; Olson EN
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):907-12. PubMed ID: 11782539
[TBL] [Abstract][Full Text] [Related]
34. Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats.
Kato T; Sano M; Miyoshi S; Sato T; Hakuno D; Ishida H; Kinoshita-Nakazawa H; Fukuda K; Ogawa S
Circ Res; 2000 Nov; 87(10):937-45. PubMed ID: 11073891
[TBL] [Abstract][Full Text] [Related]
35. Switching feedback mechanisms realize the dual role of MCIP in the regulation of calcineurin activity.
Shin SY; Choo SM; Kim D; Baek SJ; Wolkenhauer O; Cho KH
FEBS Lett; 2006 Oct; 580(25):5965-73. PubMed ID: 17046757
[TBL] [Abstract][Full Text] [Related]
36. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
Tokudome T; Horio T; Kishimoto I; Soeki T; Mori K; Kawano Y; Kohno M; Garbers DL; Nakao K; Kangawa K
Circulation; 2005 Jun; 111(23):3095-104. PubMed ID: 15939815
[TBL] [Abstract][Full Text] [Related]
37. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin and beyond: cardiac hypertrophic signaling.
Molkentin JD
Circ Res; 2000 Oct; 87(9):731-8. PubMed ID: 11055975
[TBL] [Abstract][Full Text] [Related]
39. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
40. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition.
Lim HW; De Windt LJ; Mante J; Kimball TR; Witt SA; Sussman MA; Molkentin JD
J Mol Cell Cardiol; 2000 Apr; 32(4):697-709. PubMed ID: 10756124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
